Vanda Pharmaceuticals (VNDA) reported quarterly earnings results on Wednesday, May-4-2016. The company said it had a profit of $-0.17 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.03. Analysts had a consensus of $-0.20. The company posted revenue of $33.30 million in the period, compared to analysts expectations of $32.57 million. The company’s revenue was up 50.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.10 EPS.
Vanda Pharmaceuticals closed down -0.01 points or -0.11% at $8.89 with 4,10,128 shares getting traded on Monday. Post opening the session at $8.97, the shares hit an intraday low of $8.55 and an intraday high of $9.015 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Jan 6, 2016, Mihael Hristos Polymeropoulos (President and CEO) sold 21,353 shares at $8.96 per share price. According to the SEC, on Jan 6, 2016, James Patrick Kelly (SVP, CFO, Sec & Treasurer) sold 9,564 shares at $8.96 per share price. On Jan 6, 2016, Paolo Baroldi (SVP & Chief Medical Officer) sold 12,380 shares at $8.96 per share price, according to the Form-4 filing with the securities and exchange commission.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon) Fanapt (iloperidone) Tradipitant (VLY-686) Trichostatin A and AQW051. HETLIOZ (tasimelteon) is a product for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) for which a New Drug Application (NDA) was approved by the United States Food and Drug Administration (FDA). Fanapt (iloperidone) is a product for the treatment of schizophrenia. Tradipitant (VLY-686) is a small molecule neurokinin-1 receptor (NK-1R) antagonist which is under clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.